Table 4. Univariate and multivariate analysis for PFS and OS in MBC (n = 70) patients.
| Univariate analysis | ||||
|---|---|---|---|---|
| Cox regression | PFS | OS | ||
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Age (<63 vs ≥63) | 1.337 (0.806–2.218) | 0.261 | 1.184 (0.707–1.980) | 0,521 |
| Menopausal status (pre vs post) | 1.908 (1.120–3.250) | 0.017* | 1.628 (0.964–2.923) | 0.067 |
| PS (2-3 vs 0-1) | 1.788 (0.943–3.393) | 0.075 | 1.802 (0.940–3.454) | 0.076 |
| Disease status (recurrent vs de novo) | 1.943 (1.157–3.262) | 0.012* | 2.231 (1.306–3.814) | 0.003* |
| Grade (III vs I/II) | 1.203 (0.701–2.065) | 0.503 | 1.232 (0.703–2.159) | 0.465 |
| ER status (negative vs positive) | 1.600 (0.879–2.911) | 0.124 | 1.600 (0.879–2.911) | 0.124 |
| PR status (negative vs positive) | 1.151 (0.671–1.974) | 0.609 | 1.151 (0.671–1.974) | 0.609 |
| HER2 (positive vs negative) | 1.254 (0.732–2.148) | 0.410 | 1.254 (0.732–2.148) | 0.410 |
| Visceral metastases (no vs yes) | 1.002 (0.568–1.766) | 0.996 | 1.002 (0.568–1.766) | 0.996 |
| Non-visceral metastases (yes vs no) | 1.268 (0.623–2.584) | 0.513 | 1.268 (0.623–2.584) | 0.513 |
| Bone metastases (no vs yes) | 1.321(0.798–2.187) | 0.278 | 1.083 (0.634–1.849) | 0.771 |
| miR-21 (high vs low) | 1.680 (1.009–2.799) | 0.046* | 1.589 (0.916–2.756) | 0.100 |
| miR-23b (high vs low) | 1.828 (1.101–3.035) | 0.020* | 1.299 (0.772–2.186) | 0.324 |
| miR-190 (high vs low) | 1.719 (1.038–2.846) | 0.035* | 1.143 (0.677–1.928) | 0.617 |
| miR-200b (high vs low) | 1.396 (0.834–2.336) | 0.204 | 1.893 (1.076–3.331) | 0.027* |
| miR-200c (high vs low) | 1.229 (0.752–2.010) | 0.411 | 1.096 (0.658–1.025) | 0.725 |
| miR-23b/190 (both high vs others) | 2.107 (1.225–3.623) | 0.007* | 1.362 (0.779–2.382) | 0.278 |
| Multivariate analysis | ||||
| Menopausal status (pre vs post) | 1.724 (1.006–2.953) | 0.047* | – | – |
| Disease status (recurrent vs de novo) | – | – | 2.249 (1.312–3.857) | 0.003* |
| miR-200b (high vs low) | – | – | 1.916 (1.082–3.395) | 0.026* |
| miR-23b/190 (both high vs others) | 2.054 (1.195–3.530) | 0.009* | ||
PFS, progression free survival; OS, overall survival; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; *p < 0.05.